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 Introduction 
 I would ﬁ rst like to thank the Kavli Foundation and the 
Materials Research Society for giving me the opportunity to 
present this talk. I will show the ways in which we are ﬁ ghting 
cancer with nanoparticle medicines (nanomedicines). This is 
an area where the nanoscale is very important, and I will pro-
vide some illustrations to demonstrate it. First, I will provide 
some background about cancer, and then second, I will discuss 
nanoparticles and their potential to create new ways to treat 
cancer. Nano-sized particles can have a major effect in trying to 
attack solid tumors, and I will show data from the clinic where 
we have been treating patients since 2006. 
 People have been trying to ﬁ nd a cure for cancer for a long 
time; there is evidence of writings from ancient Egypt that 
describe cancer in papyrus manuscripts from 1600 BC. Toward 
the end of the last century, cancer became the number one 
killer of Americans (in the United States) under the age of 
85, replacing heart disease. 1 The good news is that deaths due 
to heart disease have declined signiﬁ cantly over the past few 
decades, whereas deaths from cancer have remained relatively 
constant. As one might expect, based on data from the World 
Bank, 2 this phenomenon is not conﬁ ned to the United States, 
but is a worldwide problem: the total number of deaths from cancer 
is larger than the total number of deaths from malaria, HIV, and 
tuberculosis, and this number is predicted to increase signiﬁ cantly 
as the population increases. The costs of therapies to treat cancer 
have increased dramatically over the last decade or so, and this 
increase is unsustainable in the long term. The cost of cancer to 
society is not only the cost of the drugs used, but also the loss 
of life of young people, and the consequent loss of productivity. 
Healthcare costs for cancer now surpass that for all other diseases 
or injuries, including those from road accidents and heart disease; 3
thus, this is a very large problem, and one that will increase. 
 Most of us know somebody in our neighborhood, or in our 
family, who is currently undergoing cancer therapy. Patients 
suffer a signiﬁ cant loss in quality of life, whether it is acute or 
long-term side effects. We therefore have a number of reasons 
for developing new therapeutics that can lower the death rate 
and maintain a high quality of life for patients. In order to do 
this, we need to attack at least two problems: metastatic disease 
and drug-resistant disease. Cancer is a metastatic disease; it can 
spread from its original site to multiple sites simultaneously. 
If we wish to attack metastatic disease, we require therapies 
that act throughout the body. Additionally, cancer can “ﬁ ght 
back” when being treated by chemotherapeutics. When cancer 
is treated with conventional small-molecule chemotherapeutics, 
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one of the ways it can “ﬁ ght back” is to put proteins on the 
surface of the cell that act as chemical pumps. When the mol-
ecules used to treat the patient are exposed to the cancer cells, 
the cells pump the drug out, and the treatment is ineffective. 
This phenomenon is called “multidrug resistance”; the cell 
can pump drugs out even if they have never been used on the 
patient before, thus, whole classes of drugs become ineffective. 
When this happens to a patient, after numerous treatments for 
example, very little can be done. To ﬁ nd a solution to this 
problem, (1) we need to develop new therapies that can be 
administered systemically and can treat metastatic disease; 
and (2) it will not be sufﬁ cient to apply the therapy to the 
tumor itself, but we will need to move it through the tumor 
and into the cancer cells before it is released to carry out its 
cell-killing properties. This problem is much more difﬁ cult than 
just getting drugs to the tumor. 
 Current cancer treatments 
 Since 1955, the major cancer treatment has been chemotherapy. 
The ﬁ rst drug used for metastatic cancer was methotrexate; which 
was followed by a series of small molecules (e.g., Adriamycin, 
Carboplatin, and Taxol) through the 1970s to 1990s. These 
small-molecule treatments are used frequently; for example, 
billions of dollars’ worth of Taxol is sold each year. Some of 
these drugs are administered orally, but most of them are admin-
istered intravenously (IV); they move through the whole body 
by diffusion and convection, both into and throughout cells in 
the various areas they can reach. The primary function of these 
molecules is to inhibit cell division, but most of the dose quickly 
exits via the kidney and into the urine. The small amount of the 
dose that remains in the body enters all types of cells, and this 
leads to a number of different side effects. If the drug enters the 
hair follicles, it kills those cells, and the patient’s hair or eyebrows 
fall out; if it enters the cells in the gastrointestinal tract, then it 
causes vomiting; and if it enters the bone marrow, it causes loss 
of cells that make up the immune system and other blood cells. 
Hopefully, some of the drug also kills the cancer 
cells, but if the cancer has become multidrug 
resistant, this can result in a number of harmful 
side effects, with no effect on the cancer. 
 More recent treatments use “targeted, 
molecular medicines.” These can still be small 
molecules, such as Gleevec, but now antibody 
molecules that are  ∼ 1–5 nm in size are being 
used. They still can have signiﬁ cant side effects, 
but they are more selective in hitting targets. 
 Nanoscale treatment of cancer 
 I would like to ﬁ rst brieﬂ y discuss some aspects 
of tumor biology. When either primary tumors 
or metastatic tumors become larger than  ∼ 1 mm 
in size—roughly the thickness of a credit card—
they need to create new blood vessels to be able 
to bring oxygen and nutrients to continue to 
grow, so they send out signals to the current 
blood vessels to grow new ones into the tumor mass. These grow 
very quickly and are different from the normal, mature blood 
vessels in the body.  Figure 1 shows a comparison of normal 
blood vessels and those in a tumor. 4 The vasculature for normal 
cells is leaky to molecules that are  ∼ 1 nm or smaller in size; 
these are the molecules needed for nourishment. In a tumor, 
however, these vessels are formed quickly, and they are not 
completely closed, as in the case of a mature vessel, so entities 
that are tens or even hundreds of nanometers in size can leak out. 
The question is whether we can exploit this difference to intro-
duce nanoscale entities into the tumor. Of course, this requires 
an injection into the circulatory system of a patient: we want to 
move nanoparticles into a tumor, but they also pass through the 
circulatory system and enter other organs in the body. When we 
started this work in the 1990s, there was very little information 
known about the way nanoscale objects interact with these organ 
systems. Our aim is to minimize the interaction with these organ 
systems and ensure the nanoparticles enter the tumor. 
 This is illustrated in a schematic from my 1996 patent 
application ( Figure 2 ). 5 Our idea was to create a stable colloid 
(these were not called nanoparticles at that time) that could be 
built with the right properties in order to introduce them into 
tumor cells. These particles would contain chemical sensors 
that would recognize that they were inside of the cell and allow 
them to perform certain functions to release the drug. These 
were our objectives, and 15 years later, we have met all of them 
in treating patients. 
 We wanted to try and create new therapies to treat the meta-
static drug-resistant problem in a physician’s ofﬁ ce, instead of a 
research hospital, and provide a high quality of life for patients. 
Of course, to be viable, this treatment needed to be highly efﬁ -
cient. If we can create high quality of life therapeutics, we might 
be able to treat a patient for a much longer period of time. Also, 
we wanted to have a robust system, while hopefully keeping the 
costs under control. At the California Institute of Technology 
(Caltech) in the mid-1990s, we started with two approaches: 
  
 Figure 1.  Comparison of (a) normal vasculature (impermeable to entities larger than ca. 
2–4 nm) and (b) tumor vasculature (impermeable to entities larger than ca. 400–700 nm). 
Reprinted with permission from Reference 4. ©2006, National Cancer Institute. 
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one way was to try and build systems that could ultimately 
obtain FDA approval to treat patients; the other was to build 
model systems, from which we could understand some of the 
fundamental principles about the way these nanoparticles inter-
act with various tissues. Very little was known about the way 
nanoscale entities interacted with the various organs in the body. 
One of the model systems we used was gold nanoparticles func-
tionalized with polyethylene glycol (PEGylated 
gold). The research started in 1996, and in 2006, 
we were able to treat the ﬁ rst patients, which 
illustrates the time and effort required. 
 These colloidal particles are now referred to 
as “nanoparticles,” and they started to become 
signiﬁ cant in the early 2000s. I believe that one 
of the main reasons for this was the National 
Nanotechnology Initiative (NNI), which was 
started at that time. I was fortunate to be in the 
audience at Caltech when President Clinton 
announced the initiation of this program. In 
the early 2000s, the National Cancer Institute 
started their program in nanotechnology, and 
they deﬁ ned nanoparticles to be between 1 nm 
and 100 nm in size. In our efforts to attack solid 
cancers from systemic administrations, we 
found that the range is much more restrictive, 
but it is in the middle of this region. 
 Many of us were very positive about this 
approach, but others were concerned about 
the negative aspects of injecting nanoparticles 
into patients. I was asked to testify in front of 
a US Senate subcommittee on the safety of 
nanoparticles, and I explained nanoparticles 
to the senators by saying that the ratio of a 
hundred-nanometer particle to that of a soccer ball is of the same 
order of magnitude change as that of the soccer ball to planet 
Earth. The senators understood this; they knew a nanoparticle is 
supposed to be small. It is also interesting to note that a nanopar-
ticle is very large relative to a molecule, so a molecule that is 
smaller than 1 nm, compared to a 100-nm nanoparticle, has the 
same ratio as that of the soccer ball to the Goodyear blimp. I do 
not think that the senators had an appreciation for this point. We 
learned over that last decade or so that the “Goodyear blimp” is 
too large for treating solid cancers, and we require something like 
the size of a hot air balloon relative to a soccer ball. 
 We are therefore trying to learn the rules for making nanopar-
ticles on the order of 50 nm, and I will show why I believe this 
is approximately the right size. We need to ensure that these 
highly multifunctional systems perform correctly in the right 
place and at the right time. These are not passive entities; they 
must be very dynamic in order to perform the tasks required of 
them. We will consider size ﬁ rst. As an engineer, I always think 
of bounds, so what is the lower bound? For example, animal 
and human kidneys all contain holes,  ∼ 10 nm in diameter, to 
allow molecules to pass into urine. A nanoparticle larger than 
10 nm in diameter, with the right properties, can circulate in 
the blood for a number of hours, whereas a small molecule 
would escape directly into the urine. As I mentioned earlier, 
most small-molecule drugs are delivered directly into the urine, 
because they are smaller than 10 nm. This is a very ﬁ xed bound 
if we are dealing with a non-deformable spherical particle, but 
for different types of morphologies and aspect ratios, different 
results may occur.  Figure 3 shows a carbon nanotube passing 
  
 Figure 2.  Initial schematic for cancer treatment with 
nanoparticles. Issues from the initial design that have carried 
through to the clinic are cyclodextrin polymer-based colloid 
(nanoparticle), sizes below 100 nm in diameter, targeted colloid 
(R in diagram), and intracellular delivery and active mechanism 
of drug release. Reprinted with permission from Reference 5. 
©2009, American Society for Pharmacology and Experimental 
Therapeutics. 
  
 Figure 3.  Excretion of carbon nanotubes by a mouse kidney. (a) Glomerular fi ltration 
barrier. Inset: section of renal glomerulus (scale bar is 10 mm); (b) bundled MWNT 
agglomerate (circled by dashed black line) in the glomerular capillary. Individual MWNTs 
(black arrow) (c) 5 min and (d) 30 min after IV injection crossing the fi ltration membrane. 
P, podocyte; BM, basal membrane; FE, fenestrated endothelium; EC, endothelial cell; 
RBC, red blood cell. Reprinted with permission from Reference 6. ©2008, Wiley. 
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through one of the pores in a kidney. 6 , 7 Joe DeSimone, of the 
University of North Carolina at Chapel Hill, has shown that it is 
possible to make nanoparticles of any shape, and therefore the 
rules will change depending on both the shape and the aspect 
ratio. However, the rules we will discuss here are for spherical 
nanoparticles that are not very deformable. 
 What happens if we make particles greater than 10 nm in 
size? They will distribute themselves throughout the body 
and we need to make sure they disassemble; otherwise they 
will be present in the body for a long time.  Figure 4 is an 
image of 70 nm gold nanoparticles inside a kidney, where 
they will remain forever. Fitzpatrick et al. showed that even 
two years after an injection, nanoparticles that have neither 
disassembled nor dissolved are still present in the kidney. 8 
This is unacceptable for treating patients, so we need to make 
nanoparticles greater than 10 nm in size that circulate but also 
disassemble when required. 
 Now consider the upper bound. As one would expect, the 
smaller the size, the farther these particles can move from the 
vessel into the tumor tissue. It is now known that 100 nm is 
deﬁ nitely far too large, and our preference is 50 nm +/– 20 nm. 
 All tumors are different, of course, and they are all hetero-
geneous in nature, but it can be shown that for very permeable 
tumors, there is not much difference in the 100- to 30-nm 
range for penetration into the tumors. However, for tumors 
that are not very permeable, there is great discrimination in 
size range. 9 
 Very small particles have a large relative surface area com-
pared to volume, and there are cells in the body whose function 
is to scavenge nanoparticles from nature, such as viruses and 
fungi, whose surfaces are all highly electrically negative. It was 
known in the 1980s, from microspheres, that if these surfaces 
are made to be almost neutral, the scavenging is minimized, 
and as they become negative and are more similar to nature’s 
particles, the scavenging is increased. We must avoid creating 
positive surfaces in the body, because all other 
surfaces are negative. 
 Figure 5 shows a transmission electron 
microscopy (TEM) image of a section of a 
liver showing the liver cells; the Kupffer cells 
marked with a K are the cells that scavenge 
particles. 10 We made a series of nanoparticles 
with a constant zeta potential close to neutral 
and with increasing sizes from 25 nm to 160 nm. 
These nanoparticles were injected into the tail 
vein of a mouse, and the TEM images of single 
cells showed that the difference in scavenging 
in the liver cells between 100 nm and 70 nm 
was dramatic. The smaller the particles, the 
fewer remain in the cells; thus, it is clear that 
smaller is better, because we do not want to 
waste valuable therapeutics by allowing them 
to be taken up in these cells. In essence, the 
rule that applies at the microscale level is the 
same rule that applies at the nanoscale level; 
however, the smaller the nanoparticle, the less scavenging 
occurs by these cells. 
 Another point is that these particles need to engage various 
molecules on the surface of the cells they enter. If the particles 
are too small, they cannot engage enough of these molecules to 
cause the membrane to wrap around them; if they are too large, the 
membrane cannot wrap around them completely. The optimum 
size for this membrane wrapping is about 40–50 nm. 11 
 In summary, over the last decade we have learned that these 
nanoparticles must have sizes between 10 nm and 100 nm. If 
they are entering cells, they should be as close to electrically 
neutral as possible, but it is preferable to err on the side of 
negative charge. This gives us a basis for the design rules we 
require, independent of the type of drug or payload.  Figure 6 
shows a TEM image of nanoparticles with desirable properties 
  
 Figure 4.  Gold nanoparticles functionalized with polyethylene glycol (PEGylated gold) 
trapped in a kidney. ZnS capped CdSe quantum dots coated with PEG injected into Balb/c 
mice were detected two years after injection. The nanoparticles are larger than ca. 10 nm. 
Figure courtesy of Chung Hang J. Choi (Caltech). 
  
 Figure 5.  Cells in liver uptake particles; cells marked with K 
are the cells that scavenge particles. Figure courtesy of 
S.R. Popielarski (Caltech). 
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entering the cells and localizing into vesicles. 12 It is interesting 
to note that the pH is near neutral in these vesicles and becomes 
acidic as they move toward the nucleus of the cell. Therefore, 
we create chemical entities on the nanoparticles that can recog-
nize this acidity and trigger a number of changes that allow the 
drug molecules to be released. If we are using big molecules 
like RNA, we have to actively take them out of vesicles, as 
they do not diffuse through the vesicle membranes like small-
molecule drugs. These systems are highly multifunctional; 
they stay together during circulation and release the payload 
in the right place. 
 Patient treatment using nanoparticles 
 I will now describe some speciﬁ cs about two nanoparticles 
that we have been using to treat patients. The ﬁ rst one involves 
a small-molecule drug, and the second one involves RNA. 
We started to build new polymers based on a molecule called 
“cyclodextrin”; this is a ring of sugar. The reason I chose this 
molecule is primarily based on human data. The human dose 
of cyclodextrin is 8 grams in the therapeutic called Sporanox; 
for comparison, a typical dose of Advil or Motrin is 100 mg to 
200 mg—up to 1 gram or higher for arthritic patients. These 
cyclodextrin molecules have low toxicity, and my idea was 
to use these as molecular building blocks to build polymeric 
materials with high functionality. We started creating linear 
polymers, where the cyclodextrin was part of the backbone 
for a variety of reasons. The ﬁ rst nanoparticle that we created 
using cyclodextrin-containing polymers carried a small-
molecule drug called “camptothecin,” that inhibits a par-
ticular protein called “topoisomerase I,” and its mechanism 
of action would favor having the drug continually bound 
to topoisomerase I. Camptothecin itself is so toxic that it 
was never commercialized, although it is a very potent drug 
for a wide variety of different cancers. However, there are 
two commercial drugs based on the camptothecin core, but 
they have other organic functional groups on them to assist 
in their function in humans. Sales of these commercially 
available molecules have been over a billion dollars a year, 
but they have many side effects. 
 We built a polymer with repeating units of cyclodextrin 
and a PEG molecule along the backbone. This can be thought 
of as a long, ﬂ exible rope with knots in it; the knots are the 
cyclodextrins, and the rope in between is the PEG. We attached 
the camptothecin molecules to this polymer chain. When this 
polymer is placed in water, the camptothecin molecules hide 
in the cyclodextrin; they form what is called an “inclusion 
complex.” Some of the molecules on this polymer chain hide 
in the cyclodextrins of the same chain, while others also enter 
cyclodextrins on other chains When this is done correctly, 
it forms a nanoparticle of  ∼ 30 nm diameter with a slightly 
negative zeta potential that contains about 5–10 polymer 
chains. Based on our design rules, this is the right size range 
and the right charge. This nanoparticle was originally called 
IT-101, but is now denoted CRLX101. The nanoparticle must 
also be able to disassemble at the right time, because it is too 
large to escape through the kidney. Since the drug-cyclodextrin 
interaction holds the nanoparticle together, it disassembles 
into single polymer strands when the drug is released; these 
polymer strands are made of sufﬁ cient molecular weight or 
size so that an individual polymer strand is small enough to 
escape the body through the kidney. The nanoparticles will 
circulate, enter the tumor, enter cancer cells, release the drug, 
and disassemble into single strands that escape from the body 
through the urine. 
 We also used nanotechnology in order to observe these 
nanoparticles as they accumulate in tumors. We take a 5 nm 
Au nanoparticle and attach PEG molecules with adamantane 
at their termini to the gold surface, forming Au-PEG-AD. The 
adamantane molecule ﬁ ts snuggly inside the cyclodextrin 
so that it can bind to the CRLX101 nanoparticle. Since the 
Au-PEG-AD is a ﬂ uorophore, it can be used to locate the 
positions of the CRLX101 nanoparticles in a tissue sample. 
 Figure 7 shows both a cryo TEM image of the therapeutic 
particle and a cryo TEM image of the gold particles decorating 
the surface of the therapeutic particle. When we take sections 
of a tumor, we can use the Au-PEG-AD “stain” to follow the 
nanoparticles as they move into the tissue and into the cells. 
 As already mentioned, we can develop the chemistry such 
that the nanoparticle releases the drug in a pre-programmed 
way; this particular drug should be released over a long period 
of time. This means we can retain a slow release agent over a 
period of days in the tumor only. 
 After years of work, we started treating patients in the 
summer of 2006, and the first trial was performed at the 
City of Hope. We made a freeze-dried product that was then 
reformulated in water in an IV bag. The ﬂ uid in the bag was 
then infused into the patient. Several patients had survival times 
of a year or more using this treatment. 
 It is interesting to note that, while these nanoparticles 
circulate with a half-life of approximately a day in rats and dogs, 
they circulated even longer in human patients—with almost a 
two-day half-life. Patient reproducibility was excellent, which 
we believe is due to the circulation of nanoparticles not bound 
to blood components. 
  
 Figure 6.  Nanoparticles enter cells as individual particles, 
bypass surface pumps, and deliver their payloads. Reprinted 
with permission from Reference 12. ©2004, Elsevier. 
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 From the biopsies of patients 14 days after a dose, we could 
recognize from that gold stain that there were nanoparticles still 
in the tumor and releasing the drug. It was also pleasing to note 
that the side effect proﬁ le was extremely low; patients had a 
high quality of life, and there were no new side effects due to 
the presence of the nanoparticles. 
 We started to observe encouraging activity over a variety of 
different cancers, and the mechanism of long circulation and 
long drug release we observed in animals has been extended 
to humans. It is encouraging to ﬁ nd that the rules learned from 
animals may help us try to learn the rules for application to 
humans. 
 CRLX101, a product of Cerulean Pharma, is currently 
undergoing a randomized Phase II trial for a particular type 
of lung cancer; the trial involves 150 patients at more than 
25 sites, and there are a variety of other Phase II trials that will 
start in 2012. 
 RNA as a therapeutic 
 I now discuss ways of delivering a piece of RNA as a thera-
peutic. The understanding of the molecular biology of cancer 
is advancing extremely rapidly. It is now known that cells use 
many different pathways as they pass through cell growth, cell 
division, and cell death. In cancer, these pathways become 
altered, and there is an imbalance such that cells continue to 
grow all the time. We would like to develop a way to selectively 
attack multiple pathways in a patient-by-patient way. A new 
technology is available that may help us do this, called “RNA 
interference (RNAi),” in which we use a small piece of RNA 
called a “duplex.” An RNA duplex used for RNAi consists of 
two small pieces of RNA (around 20–25 base pairs), and when 
they enter cells, they can interact with some proteins within the 
cell. The proteins that incorporate one of these strands shuttle 
it to what is called “messenger RNA” (mRNA), 
line it up appropriately, and cut that mRNA at 
a very speciﬁ c spot. If the mRNA is cut, then 
the protein that is normally synthesized by that 
RNA message cannot be created. The under-
standing of this technology won the Nobel Prize 
in Medicine and Physiology in 2006 for Craig 
Mello and Andrew Fire, and they conducted 
their study using worms. It requires a large tran-
sition from worms to human patients, but my 
colleagues and I reported the ﬁ rst proof of RNAi 
in patients in 2010. Fire said, “If a person has a 
tumor, why not take a gene that’s essential for 
that tumor and administer double stranded RNA 
corresponding to that gene to shut down growth 
of that tumor?” 13 We did just that. 
 Most drugs work by binding to proteins, 
and since proteins have many different func-
tions, these drugs must be very speciﬁ c for each 
protein and each function. But if you attack the 
mRNA instead, the molecules you can use are 
essentially the same as the mRNA. The only 
thing you are doing is changing the orders of the letters on the 
duplex RNA. Thus, in principle, we can attack any gene with 
any function, whereas in the case of drugs, there are a number 
of proteins that are “undruggable” because we do not know how 
to drug or attack them. This technology, if it can be developed 
as a therapeutic, essentially changes the methodology from 
primarily chemistry to informatics. We can examine which 
genes have gone wrong and dial in appropriate sequences, but 
the chemistry is essentially the same. 
 This process is analogous to a bathtub with faucets. We 
normally turn the water on, but when we have enough water, 
we turn it off. This is similar to the way a cell knows how to 
turn functions on and off before they have mutated. When they 
mutate, the faucet is on all the time, and the cell is constantly 
making protein and the cells continue to grow; we are simply 
creating water, and the water ﬂ ows out over the tub all of the 
time. Traditional drugs work at the protein level, and they are 
spending all their time mopping up the water. The proteins 
keep being created, and the drugs keep mopping up as much 
as they can. Using RNAi, we simply turn the faucet off, 
which can be a much more efﬁ cient system to stop the pro-
duction of protein, and this is independent of the protein 
being stopped. This method has very high potential to be 
broadly applicable. 
 Consequently, we developed a nanoparticle carrying the 
RNA duplexes, again using a polymer, and some other mate-
rials to decorate the surface of the nanoparticle to help it target 
cancer cells. These pieces of RNA are large relative to che-
motherapeutics. We can construct a particle carrying about 
2000 RNA molecules as a payload. Once again, we can use the 
Au-PEG-AD stain because we are using a cyclodextrin particle. 
Thus, when we examine the tissues, we can see the particles as 
well as the position of the RNA in order to see that it is being 
  
 Figure 7.  Schematic representation and TEM of the interaction between the 5 nm 
Au-PEG-AD and 30–40 nm IT-101. The TEM images show the therapeutic particle (left) 
and gold particles decorating the therapeutic particle surface. 
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delivered throughout the tumor. We can examine individual cells 
and again show individual particles circulating from the point 
where the animal is dosed to the inside of the cancer cell. We 
started treating patients with these nanoparticles in the spring 
of 2008, and in 2010, we published the ﬁ rst results showing that 
this technology can actually be used in a living human being. 14 
 Figure 8 illustrates what we believe happens when we 
infuse these nanoparticles into the patient: (step 3) they circu-
late, (step 4) enter the tumor, and (step 5) move into the tumor 
cells. These nanoparticles contain chemical sensors that can 
recognize that they have entered the vesicles, and we have 
built in a mechanism to (step 6) bring them out of the vesicles 
and release the RNA that then will be (step 7) taken up by the 
protein machinery, guide it to the mRNA, and (step 8) cut the 
mRNA to (step 9) stop the production of protein. 5 In principle, 
if this mechanism was acting in the way we believe it is 
acting, we should see a decrease in the mRNA, a decrease in 
the protein, and a new fragment of RNA. We were fortunate 
to obtain biopsies from patients at three different dose levels: 
18, 24, and 30 mg-siRNA/m 2 . When we examined the tissues, 
we saw that for the lowest dose, using the Au-PEG-AD stain, 
we saw no nanoparticles. When we examined the intermediate 
dose, we started to see some nanoparticles, and then at the 
higher dose, we saw many nanoparticles. After a month, 
we examined biopsies of one of the patients where we saw 
the nanoparticles, and we observed that the nanoparticles had 
all disassembled (the disassembled components are sufﬁ ciently 
small to escape the body via the kidney). After a repeat dose, 
we saw the nanoparticles returning again, in a very reproducible 
manner. Thus, for the ﬁ rst time, we have seen a dose-dependent 
accumulation of these nanoparticles within tumor cells from a 
systemic administration: this is the ﬁ rst example of this using 
nanoparticles of any type. 
 A very encouraging result was to ﬁ nd that we did not see 
any nanoparticles in the tissue adjacent to the tumor. We believe 
that this is good evidence to suggest that these nanoparticles 
accumulate in tumors through the leaky vessels, but cannot 
accumulate in the healthy tissue next to the tumor. 
 When we examined the tissue through staining, we 
observed reductions in the protein we were trying to inhibit. 
When we looked for either the protein or the level of the 
mRNA, we found it is reduced. Additionally, we showed the 
presence of RNA fragments after dosing, and by sequencing 
these fragments, we revealed that the mRNA was cut at exactly 
the right position by the RNAi mechanism. This was the ﬁ rst 
example showing that we could perform RNAi in a patient. 
Thus, we have demonstrated that RNAi can be successful 
in a human patient and gives a high quality of life during 
treatment. 
 The future 
 We are now learning a great deal about design rules and how 
to control the properties of these nanoparticles to make them 
more biocompatible and more effective. The newer particles 
I have just shown have ever-increasing functionality in order 
to perform the required function at the right place and at the 
right time. There is no doubt that 
these nanoparticles will be com-
plex, but hopefully, this will be 
worth the effort. We can now 
focus on ways to create very 
effective therapeutics for solid 
tumors and give patients a high 
quality of life. 
 One thing I am very proud 
of is that we have been able to 
stop the production of an indi-
vidual gene in the tumor of the 
patient, thus there is no reason 
we cannot stop the production 
of multiple genes at the same 
time. We could take a biopsy 
from a patient, ﬁ nd which genes 
are causing their disease, create 
RNAs to treat the patient, and be 
able to follow how the treatment 
of the disease is progressing, 
maybe by simply taking a prick 
of blood. In the future, one could 
envision that there will be an app 
on a smartphone that will read 
the information from a prick of 
blood, call up a physician, and 
  
 Figure 8.  Schematic of the delivery and function of treating a patient with targeted nanoparticles 
containing RNA. 
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report the results. This will enable the physician to know how 
the disease is either regressing or progressing, and this infor-
mation could be used dynamically to decide the next dose, what 
genes it should attack, and when it should be administered to 
the patient. This is really a dream, but the basic science and 
engineering for every step of this process has already been 
worked out. It has yet to be integrated, but the basic principles 
of such a system are all in place, and every step of the way 
required new nanoscience and nanoscale engineering. My hope 
is that at least some fraction of this will be achieved in the 
near future. 
 In conclusion, I hope I have been able to convincingly show 
very high potential for the use of nanoparticles to create new 
types of therapies for treatment of solid tumors that provide 
patients with a high quality of life. It is very encouraging for 
me to see patients in these early clinical trials having a high 
quality of life when treated with these therapies. 
 I have had the great privilege of working with wonderful 
people everywhere—at Caltech, and with various companies. 
I would very much like to thank all the patients who have 
been treated in these trials. It has been a pleasure for me to 
be present in the treatment rooms with them in a number of 
different trials. Finally, I would once again like to thank the 
Kavli Foundation, and MRS, for giving me the opportunity to 
speak with you tonight. 
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